HNGE
VENTE TOTALE: 1 200 titres (~105 876,00 $ US)
- Insiders
- Leslie Kristina M
- Total bought
- —
- Total sold
- $105,876
- Last activity
- 2026-08-20
- Last synced
-
2026-08-26 03:23:35
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-26
HNGE presents a deeply unfavorable risk/reward profile: despite a promising earnings catalyst (53% revenue growth, raised 2026 outlook, and the $135B Cylinder GI opportunity), the extremely weak fundamental health score…
The first sentence of the analysis written for HNGE on 2026-08-26 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Gross Profit Margin | 79.8% | 77.0% | 66.3% | |
| Ebit Margin | -92.0% | -6.3% | -44.6% | |
| Ebitda Margin | -91.2% | -5.7% | -43.9% | |
| Operating Profit Margin | -92.9% | -8.2% | -44.6% | |
| Pretax Profit Margin | -89.7% | -2.9% | -37.1% | |
| Continuous Operations Profit Margin | -89.9% | -3.1% | -36.9% | |
| Net Profit Margin | -89.9% | -3.1% | -36.9% | |
| Bottom Line Profit Margin | -72.1% | -3.1% | -36.9% | |
| Current Ratio | 1.473 | 2.340 | 2.877 | |
| Quick Ratio | 1.430 | 2.297 | 2.805 | |
| Solvency Ratio | -1.428 | -0.037 | -0.543 | |
| Cash Ratio | 0.574 | 1.207 | 1.276 | |
| Price To Earnings Ratio | -8.666 | -250.400 | -27.022 | |
| Price To Earnings Growth Ratio | -0.002 | 2.807 | 0.000 | |
| Forward Price To Earnings Growth Ratio | -0.002 | 2.807 | 0.000 | |
| Price To Earnings Diluted Ratio | -8.950 | -250.400 | -27.022 | |
| Price To Earnings Diluted Growth Ratio | -0.003 | 2.807 | 0.000 | |
| Price To Book Ratio | 9.717 | 7.032 | 6.858 | |
| Price To Sales Ratio | 6.257 | 7.506 | 10.010 | |
| Price To Free Cash Flow Ratio | 21.545 | 64.788 | -42.763 | |
| Price To Operating Cash Flow Ratio | 21.456 | 59.799 | -45.851 | |
| Debt To Assets Ratio | 0.011 | 0.016 | 0.025 | |
| Debt To Equity Ratio | 0.021 | 0.027 | 0.037 | |
| Debt To Capital Ratio | 0.021 | 0.026 | 0.036 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.967 | 1.616 | 1.457 | |
| Working Capital Turnover Ratio | 2.325 | 1.148 | 0.000 | |
| Operating Cash Flow Ratio | 0.473 | 0.197 | -0.347 | |
| Operating Cash Flow Sales Ratio | 0.292 | 0.126 | -0.218 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.996 | 0.923 | 1.072 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 21.326 | 4.426 | -4.062 | |
| Capital Expenditure Coverage Ratio | 242.148 | 12.988 | -13.848 | |
| Dividend Paid And Capex Coverage Ratio | 242.148 | 12.988 | -13.848 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -6.491 | -119.596 | -21.116 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 79.8% | ▲2.8% | ▲5.5% |
| Ebit Margin | -92.0% | ▼-85.8% | ▼-44.4% |
| Ebitda Margin | -91.2% | ▼-85.5% | ▼-44.3% |
| Operating Profit Margin | -92.9% | ▼-84.8% | ▼-44.4% |
| Pretax Profit Margin | -89.7% | ▼-86.8% | ▼-46.5% |
| Continuous Operations Profit Margin | -89.9% | ▼-86.8% | ▼-46.6% |
| Net Profit Margin | -89.9% | ▼-86.8% | ▼-46.6% |
| Bottom Line Profit Margin | -72.1% | ▼-69.1% | ▼-34.8% |
| Current Ratio | 1.473 | ▼-0.867 | ▼-0.757 |
| Quick Ratio | 1.430 | ▼-0.867 | ▼-0.747 |
| Solvency Ratio | -1.428 | ▼-1.391 | ▼-0.759 |
| Cash Ratio | 0.574 | ▼-0.633 | ▼-0.445 |
| Price To Earnings Ratio | -8.666 | ▲241.734 | ▲86.697 |
| Price To Earnings Growth Ratio | -0.003 | ▼-2.809 | ▼-0.937 |
| Forward Price To Earnings Growth Ratio | -0.003 | ▼-2.809 | ▼-0.937 |
| Price To Earnings Diluted Ratio | -8.950 | ▲241.450 | ▲86.507 |
| Price To Earnings Diluted Growth Ratio | -0.003 | ▼-2.810 | ▼-0.937 |
| Price To Book Ratio | 9.717 | ▲2.685 | ▲1.848 |
| Price To Sales Ratio | 6.257 | ▼-1.248 | ▼-1.667 |
| Price To Free Cash Flow Ratio | 21.545 | ▼-43.243 | ▲7.022 |
| Price To Operating Cash Flow Ratio | 21.456 | ▼-38.343 | ▲9.654 |
| Debt To Assets Ratio | 0.011 | ▼-0.006 | ▼-0.007 |
| Debt To Equity Ratio | 0.021 | ▼-0.005 | ▼-0.007 |
| Debt To Capital Ratio | 0.021 | ▼-0.005 | ▼-0.007 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.968 | ▲0.352 | ▲0.287 |
| Working Capital Turnover Ratio | 2.325 | ▲1.177 | ▲1.167 |
| Operating Cash Flow Ratio | 0.473 | ▲0.277 | ▲0.365 |
| Operating Cash Flow Sales Ratio | 0.292 | ▲0.166 | ▲0.225 |
| Free Cash Flow Operating Cash Flow Ratio | 0.996 | ▲0.073 | ▼-0.001 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 21.326 | ▲16.900 | ▲14.096 |
| Capital Expenditure Coverage Ratio | 242.148 | ▲229.161 | ▲161.719 |
| Dividend Paid And Capex Coverage Ratio | 242.148 | ▲229.161 | ▲161.719 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -6.491 | ▲113.105 | ▲42.577 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Market cap | $3.68B | $2.93B | $2.93B | |
| Enterprise value | $3.48B | $2.64B | $2.71B | |
| EV / Sales | 5.92x | 6.76x | 9.26x | |
| EV / Op. cash flow | 20.29x | 53.89x | -42.42x | |
| EV / Free cash flow | 20.37x | 58.38x | -39.56x | |
| EV / EBITDA | -6.49x | -119.60x | -21.12x | |
| Net debt / EBITDA | 0.37x | 13.12x | 1.71x | |
| Current ratio | 1.47x | 2.34x | 2.88x | |
| Income quality | -0.33x | -4.11x | 0.59x | |
| Graham net-net | $1 | $3 | $3 | |
| Tax burden | 100.2% | 106.0% | 99.6% | |
| Interest burden | 97.5% | 46.1% | 83.2% | |
| Working capital | $171.5M | $334.1M | $345.7M | |
| Invested capital | $255.5M | $414.5M | $432.0M | |
| Return on assets | -70.9% | -1.8% | -17.4% | |
| Operating ROA | -77.1% | -4.9% | 0.0% | |
| Return on tangible assets | -77.9% | -2.0% | -19.4% | |
| Return on equity | -139.6% | -2.9% | -25.3% | |
| Return on invested capital | -141.3% | -7.5% | -29.4% | |
| Return on capital employed | -142.9% | -7.5% | -29.8% | |
| Earnings yield | -14.4% | -0.4% | -3.7% | |
| Free cash flow yield | 4.6% | 1.5% | -2.3% | |
| Capex / Op. cash flow | 0.4% | 7.7% | -7.2% | |
| Capex / Depreciation | 12.9% | 63.4% | 82.0% | |
| Capex / Sales | 0.1% | 1.0% | 1.6% | |
| SG&A / Sales | 108.8% | 58.3% | 73.3% | |
| R&D / Sales | 62.6% | 25.8% | 37.6% | |
| Stock comp / Sales | 109.4% | 0.2% | 0.6% | |
| Intangibles / Total assets | 8.9% | 9.4% | 10.2% | |
| Days sales outstanding | 41d | 40d | 58d | |
| Days payables outstanding | 0d | 0d | 0d | |
| Operating cycle | 89d | 84d | 107d | |
| Cash conversion cycle | 89d | 84d | 107d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+25.5%EV / Sales ▼-12.5%EV / EBITDA ▲+94.6%EV / Op. cash flow ▼-33.597Earnings yield ▼-0.140
Profitability
Return on equity ▼-1.367Return on assets ▼-0.692Return on invested capital ▼-1.339Return on capital employed ▼-1.354Operating ROA ▼-0.721Income quality ▲+3.782Tax burden ▼-0.058
Efficiency
Days sales outstanding ▲+1.287Days payables outstanding n/aOperating cycle ▲+5.236Cash conversion cycle ▲+5.236Capex / Sales ▼-0.008R&D / Sales ▲+0.368
Balance-sheet strength
Current ratio ▼-0.867Net debt / EBITDA ▼-12.749Working capital ▼-162652000.000Invested capital ▼-159094000.000Intangibles / Total assets ▼-0.005
Change over 5 years
Valuation
Market cap ▲+25.5%EV / Sales ▼-36.1%EV / EBITDA ▲+69.3%EV / Op. cash flow ▲+62.710Earnings yield ▼-0.107
Profitability
Return on equity ▼-1.142Return on assets ▼-0.536Return on invested capital ▼-1.120Return on capital employed ▼-1.131Operating ROA n/aIncome quality ▼-0.916Tax burden ▲+0.006
Efficiency
Days sales outstanding ▼-17.042Days payables outstanding n/aOperating cycle ▼-18.136Cash conversion cycle ▼-18.136Capex / Sales ▼-0.015R&D / Sales ▲+0.250
Balance-sheet strength
Current ratio ▼-1.404Net debt / EBITDA ▼-1.334Working capital ▼-174230000.000Invested capital ▼-176542000.000Intangibles / Total assets ▼-0.013
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-21 IPO Stock Of The Week: Hinge Health Finds Support At Key Level, Eyes New Buy Points Hinge stock found support at a key level in recent weeks and is approaching multiple new buy points despite market weakness.
- 2026-08-20 One Platform, Every Ailment: Hinge Health''s Gamble Many people know that seemingly unrelated symptoms can be connected. But in most cases, treating individual symptoms means a separate doctor visit, sometimes to different specialists, before the full picture emerges.
- 2026-08-19 HNGE Stock Surges Nearly 90% YTD: Can Its Growth Story Continue? Hinge Health''s nearly 90% YTD surge is backed by 53% revenue growth, wider margins and expansion into migraine and GI care, but execution risks remain.
- 2026-08-14 Reasons to Hold Hinge Health Stock in Your Portfolio for Now HNGE''s strong revenue growth, raised 2026 outlook and expansion into Migraine and GI care support its growth prospects despite investment pressures.
- 2026-08-12 Is Hinge Health Stock a Buy as Growth Accelerates and Risks Rise? HNGE''s rapid revenue growth, widening margins and higher 2026 outlook strengthen its case, but expansion raises execution risks.
- 2026-08-12 Hinge Health''s Cylinder Deal Opens a $135B GI Care Growth Opportunity HNGE''s $105 million Cylinder deal opens a $135 billion GI care market, adding nearly 100 clients and about 2 million lives.
- 2026-08-12 HNGE Rallies 64.6% in 3 Months as Growth and Margins Gain Momentum Hinge Health 64.6% three-month rally is backed by surging revenues, wider margins and a raised 2026 outlook, but execution expectations are rising.
- 2026-08-12 Is the Options Market Predicting a Spike in Hinge Health Stock? Investors need to pay close attention to HNGE stock based on the movements in the options market lately.
- 2026-08-12 Jim Cramer Recommends Buying This Health Care Stock: ‘What A Quarter They Had'' On CNBC''s “Mad Money Lightning Round,” Jim Cramer said Hinge Health, Inc. (NYSE:HNGE) is a buy. “What a quarter they had,” he added.
- 2026-08-12 Assenagon Asset Management S.A. Invests $6.87 Million in Hinge Health Inc. $HNGE Assenagon Asset Management S.A. bought a new stake in shares of Hinge Health Inc. (NYSE: HNGE) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 82,740 shares of the company''s stock, valued at approximately $6,867,000. Assenagon Asset Management S.A. owned approximately